Ustekinumab Biosimilars Market Estimations (2025 - 2035)
The ustekinumab biosimilars market covers biosimilars referencing Stelara (ustekinumab), an IL-12/23 antibody, in subcutaneous prefilled syringe and autoinjector forms and intravenous induction vials, branded, unbranded and private-label, interchangeable and non-interchangeable, for plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
📄Report ID:2516
|
📊Format: Databook
|
📅Published: 19 November 2026
|
⚡Delivery: Immediate